Nicole Saphier writing for Fox. She gets a few thi
Post# of 154064
(Total Views: 888)
Posted On: 08/23/2020 7:47:24 PM
Nicole Saphier writing for Fox. She gets a few things wrong though....https://www.foxnews.com/opinion/coronavirus-plasma-therapy-promising-step-dr-nicole-saphier
"In a similar vein, as we move forward exploring antibody therapy, monoclonal (lab manufactured) antibodies (mAbs) are declaring their role in treating COVID-19. Specifically, Leronlimab, created by a lesser-known biotech company CytoDyn, is currently enrolling two placebo-controlled double-blind clinical trials that have already entered Phase 3. Phase 2 results reported in July passed all safety checks.
Originally manufactured as an investigational injectable for HIV, Leronlimab is also demonstrating an ability to prevent and/or lessen the cytokine storm that causes much of the severity in COVID-19 symptoms. Albeit a small sample size, early Phase 1 results showed patients on Leronlimab experienced 63% less seriously adverse events than the control group, while also demonstrating reduction in viral load to zero after 14 days.
While all of this is promising, Phase 2 efficacy data has not been released yet. If that data demonstrate similar results to Phase 1, an EUA may be in the near future for this medication while Phase 3 enrollment is ongoing.
"In a similar vein, as we move forward exploring antibody therapy, monoclonal (lab manufactured) antibodies (mAbs) are declaring their role in treating COVID-19. Specifically, Leronlimab, created by a lesser-known biotech company CytoDyn, is currently enrolling two placebo-controlled double-blind clinical trials that have already entered Phase 3. Phase 2 results reported in July passed all safety checks.
Originally manufactured as an investigational injectable for HIV, Leronlimab is also demonstrating an ability to prevent and/or lessen the cytokine storm that causes much of the severity in COVID-19 symptoms. Albeit a small sample size, early Phase 1 results showed patients on Leronlimab experienced 63% less seriously adverse events than the control group, while also demonstrating reduction in viral load to zero after 14 days.
While all of this is promising, Phase 2 efficacy data has not been released yet. If that data demonstrate similar results to Phase 1, an EUA may be in the near future for this medication while Phase 3 enrollment is ongoing.
(2)
(0)